Long-term Persistence, Safety and Efficacy Profile of Dupilumab in Atopic Dermatitis: A Real-world Retrospective Multicenter Study From Spain.

Understanding senna risks: Evidence from the FDA adverse event reporting system.

Real-World Experience With Secukinumab for Hidradenitis Suppurativa: A Multicenter Retrospective Analysis of 263 Patients From the SECU-SPAIN Study.

Oxaliplatin-artesunate conjugate intensifies suppression on colorectal cancer by boosting antitumor immunity.

To evaluate the safety and efficacy of dazdotuftide (TRS01 eye drops), a novel, steroid-free, anti-inflammatory drug in patients with active anterior noninfectious uveitis (NIU), following previous studies in which it had shown a favorable risk/benefit profile with regards to safety and specifically intraocular pressure (IOP) safety profile. A randomized, double-masked, multicenter, active-controlled phase 3 trial. Adults (≤75 years of age) and pediatric patients, with active anterior NIU, with or without uveitic glaucoma, on stable medical therapy for NIU or who had received no prior therapy, requiring further treatment for an active NIU flare-up. Patients eligible for inclusion had Anterior Chamber Cell (ACC) Grade 2 or Grade 3 on Visual Analog Scale in the study eye. Patients were randomized 2:1 to topical TRS01 1% or prednisolone acetate 1% administered 4 times daily for 28 days. Key ocular assessments included slit-lamp examination, ocular pain, Best Corrected Visual Acuity, IOP and dilated ophthalmoscopy. Resolution of inflammation (ACC = 0), clinically meaningful improvement of ACC, ocular pain, flare, and IOP changes on Day 28. The Full Analysis Set included 136 patients; the mean age was 43 years in the TRS01 arm and 42 years in the prednisolone acetate arm. 48% of TRS01 vs 68% of prednisolone acetate patients achieved ACC Grade = 0 on Day 28 (95.1% Confidence Interval (CI): -0.37, -0.02; P = .0311) and 64% of TRS01 vs 89% prednisolone acetate patients experienced clinically meaningful improvement of ACC Grade = 0 or 1, ie, ≤5 cells (95.1% CI: -0.33, -0.06; P = .0049). While TRS01 was found to be inferior to topical steroids to control ACC, TRS01 was noninferior to topical steroids to control flare and ocular pain and exhibited a superior IOP safety compared to topical steroids. For patients who reached ACC = 0, TRS01-treated patients benefited from statistically significantly improved safety outcomes for IOP (including change from baseline and at each IOP threshold evaluated [P < .05]) versus steroid-treated patients. TRS01 offers the potential to serve as an effective and safe treatment option in NIU that meets the urgent need for a drug that controls inflammation without the steroids' associated risk of IOP elevation.

Integrating GC-MS analysis, ADMET, and in vivo experimental validation to deciphering the toxicological profile of the aqueous extract of the mixture of Dacryodes edulis (G. Don) H.J. Lam (Burseraceae) and Allium ampeloprasum var. porrum L. (Amaryllidaceae).

Comparison of rTMS and esketamine for treatment-resistant depression: A target trial emulation.

Real-world comparative effectiveness of atezolizumab versus durvalumab for extensive-stage small-cell lung cancer.

Total joint replacement is one of the most successful interventions in modern orthopedics, but long-term outcomes depend on effective osseointegration. Pharmacological strategies such as bisphosphonates, estrogens, and monoclonal antibodies can enhance bone-implant integration, but their clinical use is limited by adverse effects. Nutraceuticals, including polyphenols, carotenoids, and polyunsaturated fatty acids, have emerged as promising adjuncts to support bone health and osseointegration, thanks to their safety profile and biological activity. This review summarizes the molecular mechanisms involved in osseointegration, analyzes preclinical and clinical evidence on nutraceuticals, and critically assesses their translational potential. These compounds promote osteoblastogenesis, inhibit osteoclast differentiation, and mitigate oxidative stress, thereby improving peri-implant bone stability. Despite encouraging results, the clinical translation of nutraceuticals remains limited. Most available data are preclinical or based on surrogate endpoints such as bone mineral density, whereas true clinical success is determined by bone-to-implant contact and implant survival, which are rarely investigated in randomized controlled trials (RCTs). Advances in bioavailability strategies (liposomes, nanoemulsions, nanostructured lipid carriers) may improve systemic exposure, but future research must standardize dosages and provide high-quality RCTs to clarify the role of nutraceuticals as complementary tools in orthopedic implant surgery.

Marine natural product-inspired 2-(3,4,5-trimethoxybenzoyl)quinazolin-4(3H)-one derivative CHNQD-01522: A novel anti-hepatocellular carcinoma agent targeting colchicine binding site of microtubule.

Lipid-stabilized ICG nanoaggregates for the photodisruption of vitreous opacities.

Oligopeptides from Gynura divaricata improve glycemic control via inhibition of gluconeogenesis and gut-brain axis regulation.

Bionic design based on liposome-exosome hybrid nanoparticles for synergistic delivery of paeonol to achieve neuroprotection and improvement of motor function in Parkinson's disease model mice.

A novel bridged Dicarboximide derivative: A highly effective antifungal agent for managing plant pathogens.

Unveiling the genus Taraxacum: From folk medicine to chemodiversity-driven pharmacological and toxicological outcomes-A systematic review.

The opioid epidemic and limitations of current nonopioid analgesics have created a need for safer, effective pain therapies. Suzetrigine, a first-in-class selective NaV1.8 inhibitor, was approved by the Food and Drug Administration in 2025 for the treatment of moderate to severe acute pain. The purpose of this review is to discuss the mechanism and clinical efficacy of suzetrigine and its potential for addressing existing therapeutic gaps in pain management. Phase 3 trials have demonstrated that suzetrigine provides a statistically significant and clinically meaningful reduction in acute postoperative pain compared to placebo, with efficacy similar to hydrocodone/acetaminophen and a favorable safety profile. Mechanistic studies confirm selective peripheral NaV1.8 inhibition, minimizing central nervous system effects and abuse potential. Ongoing research is evaluating suzetrigine for chronic pain conditions including diabetic peripheral neuropathy and lumbosacral radiculopathy, though long-term efficacy and safety remain to be established. Suzetrigine represents a promising nonopioid alternative for acute pain and has the potential to fill a significant gap in pain management. While initial results are encouraging, future studies are needed to define its role in chronic pain and multimodal analgesia, and to establish long-term safety.

Discovery of HDM2004, a potent, selective and orally bioavailable HPK1 inhibitor for tumor immunotherapy.

Probiotic and prebiotic interventions in burn patients: A systematic review.

Clinical outcomes and safety of SGLT2 inhibitors in the older population with heart failure: A systematic review and meta-analysis.

Introduction: Infraclavicular brachial plexus blocks provide effective surgical anaesthesia and postoperative analgesia for upper limb surgeries. The use of adjuvants with local anaesthetics has gained significant attention for enhancing block quality, prolonging the duration of analgesia, and reducing postoperative opioid requirements. Both dexmedetomidine and dexamethasone have emerged as promising adjuvants; however, their comparative efficacy in infraclavicular blocks remains under investigation. Aim: To compare the efficacy of dexmedetomidine versus dexamethasone as adjuvants to 0.5% ropivacaine in ultrasoundguided infraclavicular brachial plexus block. Materials and Methods: The present triple-blinded, randomised controlled trial was conducted on 58 American Society of Anesthesiologists (ASA) physical status I-II patients undergoing elective forearm surgery between August 2023 and October 2024 at PBMH, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India. Group I (n=29) received 20 mL of 0.5% ropivacaine with 8 mg dexamethasone, while Group II (n=29) received 20 mL of 0.5% ropivacaine with dexmedetomidine (1 µg/ kg). The primary outcome was the duration of sensory block. Secondary outcomes included the onset of sensory and motor block, duration of motor block, time to first analgesic request, total analgesic requirements, haemodynamic parameters, and adverse effects. Data were analysed using unpaired t-tests and Mann-Whitney U tests for continuous variables, and Fisher’s exact test for categorical variables. Repeated measures Analysis of Variance (ANOVA) was used for haemodynamic parameters (p&lt;0.05 considered significant). Results: The mean age was 38.83±11.57 years in Group I and 39.97±13.51 years in Group II, with comparable gender distribution (male/female: 15/14 vs. 12/17), Body Mass Index (BMI) (24.35±2.86 vs. 24.12±4.13 kg/m2 ), and ASA status. Group II (dexmedetomidine) demonstrated a significantly faster onset of sensory block (7.69±2.09 vs. 9.83±1.98 minutes, p&lt;0.01) and motor block (11.24±2.34 vs. 13.21±1.88 minutes, p&lt;0.01). The duration of sensory block (792.8±170.8 vs. 610.3±89.38 minutes; p&lt;0.01) and motor block (667.8±152.6 vs. 535.9±88.7 minutes; p&lt;0.01) was significantly prolonged in the dexmedetomidine group. Time to first analgesic requirement was 883.4±159.5 versus 706.6±100.5 minutes (p&lt;0.01), with 24-hour tramadol consumption of 135.69±57.64 versus 189.32±64.05 mg (p&lt;0.01) in Groups II and I, respectively. Haemodynamic parameters remained stable in both groups, with no significant differences in adverse effects. Conclusion: Dexmedetomidine (1 µg/kg) as an adjuvant to 0.5% ropivacaine in infraclavicular brachial plexus blocks provides a faster onset, prolonged duration of analgesia, and reduced postoperative analgesic requirements compared to dexamethasone (8 mg), with a comparable safety profile.